Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes
Authors:
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 159, 104996
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisPLOS ONE, 2016
- A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes ( AWARD ‐8)Diabetes, Obesity and Metabolism, 2016
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)Diabetes Care, 2015
- Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-pointsCurrent Medical Research and Opinion, 2015
- Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority studyThe Lancet, 2015
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trialThe Lancet, 2014
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)Diabetes Care, 2014
- Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)Diabetes Care, 2014
- Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)Diabetes Care, 2014
- The Physiology of Glucagon-like Peptide 1Physiological Reviews, 2007